Cargando…

Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies

The immunomodulatory drug lenalidomide is used for the treatment of certain hematologic malignancies, including myelodysplastic syndromes (MDS). Lenalidomide interacts with cereblon (CRBN), a component of the CRL4(CRBN) E3 ubiquitin ligase complex, leading to ubiquitination and subsequent degradatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Aixia, Fang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518522/ https://www.ncbi.nlm.nih.gov/pubmed/32984863 http://dx.doi.org/10.33696/immunology.2.049

Ejemplares similares

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
por: Park, Isaac, et al.
Publicado: (2021)

Heterogeneous Myeloid Cells in Tumors
por: Dou, Aixia, et al.
Publicado: (2021)

Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009)

Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015)

Cyclosporin-A associated malignancy
por: Durnian, Jonathan M, et al.
Publicado: (2007)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012)

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
por: Negoro, Eiju, et al.
Publicado: (2016)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022)

Antitumor effect of lenalidomide in malignant glioma cell lines
por: Hanashima, Yuya, et al.
Publicado: (2020)

In vivo bioprinting: Broadening the therapeutic horizon for tissue injuries
por: Zhao, Wenxiang, et al.
Publicado: (2023)

Action potential broadening in a presynaptic channelopathy
por: Begum, Rahima, et al.
Publicado: (2016)

Broadening the Scope…
por: Bradshaw, Ralph A.
Publicado: (2020)

Therapeutic targeting of the inflammasome in myeloid malignancies
por: Chakraborty, Samarpana, et al.
Publicado: (2021)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
por: Sperling, Adam S., et al.
Publicado: (2022)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Broadening the scope of sortagging
por: Dai, Xiaolin, et al.
Publicado: (2019)

GESSS work broadens
Publicado: (1976)

Diffraction Line Broadening Analysis if Broadening Is Caused by Both Dislocations and Limited Crystallite Size
por: Kamminga, J.-D., et al.
Publicado: (2004)

The Journal of Therapeutic Ultrasound: broadening knowledge in a rapidly growing field
por: Muratore, Robert, et al.
Publicado: (2013)

An antidote approach to reduce risk and broaden utility of antibody-based therapeutics
por: Portnoff, Alyse D., et al.
Publicado: (2017)

Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations
por: Zhang, Fangliang, et al.
Publicado: (2022)

Neutrino Induced Doppler Broadening
por: Jolie, J., et al.
Publicado: (2000)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Cyclosporine and prednisolone combination therapy as a potential therapeutic strategy for relentless placoid chorioretinitis
por: Uraki, Takehiko, et al.
Publicado: (2019)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
por: Martiniani, Roberta, et al.
Publicado: (2012)

Broadening the Tent with Intentional Spaces
por: Mailhot Vega, Raymond B.
Publicado: (2020)

Broadening the Scope (Part II)…
por: Bradshaw, Ralph A., et al.
Publicado: (2020)

Broadening the definition of a bioinformatician
por: Smith, David Roy
Publicado: (2015)

Broadening the reach of Health Expectations
por: Chew‐Graham, Carolyn A.
Publicado: (2017)

Broadening Your Organizational Perspective
por: Velsor, Ellen
Publicado: (2013)

Resummation of the jet broadening in DIS
por: Dasgupta, M., et al.
Publicado: (2001)

Spectral line broadening by plasmas
por: Griem, Hans
Publicado: (2012)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u752r6nbrf5pqvn9vn69mbrjqc